NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Reconsideration of Strontium Ranelate

TA160/1 Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the primary/ secondary prevention of osteoporotic fragility fractures in postmenopausal women

Appraisal Committee Meeting – 20 October 2010

History of the appraisals' development

Date	
2002	Remit received from Department of Health
Dec 03	ACD issued
Feb 04	Decision to split appraisal into primary and secondary prevention
May 04	ACD issued
June 04	FAD issued (for secondary prevention)
Oct 04	APPEAL HEARING (dismissed)
Jan 05	Guidance issued on secondary prevention (TA87)
2004	Strontium Ranelate Appraisal starts
2005	Strontium Ranelate included in the appraisal of the other drugs (alendronate, risedronate, etidronate, risedronate, teriparatide)
Sep 05	2 ACDs issued (primary and review of secondary) followed by more economic modelling
Sep 06	2 ACDs issued (primary and secondary) followed by discussion with GDG about separating initial and subsequent treatment
Feb 07	2 ACDs for initiation of treatment only released
Apr 07	2 FADs for initiation of treatment only released:

Oct 2007	APPEAL HEARING (upheld)
March 2008	2 ACDs issued (including both initial and subsequent treatment, for both primary and secondary prevention)
May 2008	2 FADs issued (including both initial and subsequent treatment, for both primary and secondary prevention)
Oct 2008	APPEAL HEARING (dismissed)
Feb 2009	JUDICIAL REVIEW HEARING leading to consultation on executable model
Nov 2009	updated FADs issued including the consideration of comments on executable model
Dec 2009	COURT OF APPEAL HEARING on subgroup issue